Mosunetuzumab-axgb

(Lunsumio®)

Mosunetuzumab-axgb

Latest News

loading GIF

Drug updated on 4/18/2024

Dosage FormInjection (intravenous; 1 mg/mL, 30 mg/30 mL [1 mg/mL] single-dose vials)
Drug ClassCD20-directed CD3 T-cell engagers
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Mosunetuzumab-axgb (Lunsumio) is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. It has a better tolerability profile compared to PI3K inhibitors, evidenced by fewer discontinuations due to adverse events.
  • Two studies provided insights into Lunsumio's safety and effectiveness in comparison with other treatments such as Tazemetostat, PI3K inhibitors, CART therapies, and anti-CD20 antibody-based regimens.
  • Findings suggest that mosunetuzumab may present fewer safety concerns than intense CART therapies. However, direct comparisons are limited due to differences in study design.
  • In terms of effectiveness, mosunetuzumab demonstrates superior outcomes over Tazemetostat in EHZ2 wild-type patients and over PI3K inhibitors for complete response (CR) and objective response rate (ORR). Comparisons slightly favored CART therapies over Mosunetuzumab for progression-free survival, but data supporting this is not straightforward.
  • When compared with real-world data cohorts, significantly higher overall response rates (ORR) and complete response rates (CR) were observed in the Mosunetuzumab cohort, suggesting it could offer a meaningful clinical benefit over conventional third-line treatments.
  • The documented effectiveness of mosunetuzumab in EHZ2 wild-type patients highlights its potential benefits within specific genetic subgroups while also demonstrating its efficacy outside controlled clinical trial environments.